Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/162720
Title: | Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study |
Author: | Corominas, Héctor Alegre, Cayetano Narváez García, Francisco Javier Fernández-Cid, Carlos Marras Torrente Segarra, Vicenç Gómez Rodríguez, Manuel Maceiras Pan, Francisco Morlà, Rosa Martínez Rodríguez, Fernando José Gómez-Centeno, Antoni Losada Ares, Laura Gonzalez Molina, Rocío Paredes González-Albo, Silvia Dalmau-Carolà, Joan Pérez-García, Carolina Barbazán Álvarez, Ceferino Ercole, Liliana Terrancle, Maria Ángeles ACT-AXIS Study Group. |
Keywords: | Fatiga Artritis reumatoide Farmacologia Fatigue Rheumatoid arthritis Pharmacology |
Issue Date: | 29-Jun-2019 |
Publisher: | Lippincott, Williams & Wilkins. Wolters Kluwer Health |
Abstract: | To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years). Mean change in C-reactive protein level from baseline to week 12 was -11.2 ± 4.0 (P < .001). Mean Disease Activity Index score (DAS28) decreased from 5.5 ± 1.0 at baseline to 2.7 ± 1.3 (P < .001) at week 24. Mean change in Functional Assessment of Chronic Illness Therapy score was -5.4 ± 11.2 points at week 24. Multiple regression analysis showed that the improvement in DAS28, sleep, and depression explained 56% and 47% of fatigue variance at week 12 and 24, respectively.Tocilizumab is effective in reducing disease activity and results in a clinically significant improvement in fatigue, pain, swollen joint count, morning stiffness, sleepiness, depression, and DAS28; the last 3 were specifically identified as factors explaining fatigue variance with the use of TCZ in RA patients. |
Note: | Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000015947 |
It is part of: | Medicine, 2019, vol. 98, num. 26, p. 15947 |
URI: | https://hdl.handle.net/2445/162720 |
Related resource: | https://doi.org/10.1097/MD.0000000000015947 |
ISSN: | 0025-7974 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
692535.pdf | 394.2 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License